Public Funding for Anastasis Biotec Limited

no public description

Cancer relapse and metastatic spread is a serious health problem and may be caused by the inability to destroy all residual tumour cells, particularly the residual and resistant cancer stem cell (CSC) sub-population. Killing CSC has been a major technological challenge as they share similar cell pathways and features with critical normal stem cells. NOTCH signalling is a major pathway in CSC but several approaches developed to block NOTCH such as antibodies and small molecule gamma-secretase inhibitors (GSIs) have shown toxicity and limited clinical benefit. We have discovered and developed a novel peptide inhibitor of the NOTCH pathway, named Syntana-4, that has the potential to kill CSC and in combination with other treatments such as chemotherapy, reduce the likelihood of relapse and tumour recurrence and metastasis. In this project, we propose to test Syntana-4's stability after contract manufacturing, biological efficacy and safety in a variety of NOTCH mutated cancer models to support its clinical development for prostate cancer which has high levels of activated NOTCH.